Dysregulation of the fibroblast growth factor system in major depression
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
In this report we describe findings that imply dysregulation of several fibroblast growth factor (FGF) system transcripts in frontal cortical regions of brains from human subjects with major depressive disorder (MDD). This altered gene expression was discovered by microarray analysis of frontal cortical tissue from MDD, bipolar, and nonpsychiatric control subjects and was verified by quantitative real-time PCR analysis and, importantly, in a separate cohort of MDD subjects. Furthermore, we show, through a separate analysis of specific serotonin reuptake inhibitor (SSRI)-treated and non-SSRI-treated MDD subjects that the observed changes in expression of FGF transcripts are not secondary to drug treatment. Rather, changes in specific FGF transcripts are attenuated by SSRIs and may thus be partially responsible for the mechanism of action of these drugs. We also make available the gene-expression profile of all of the other growth factors and growth factor receptors detected in these postmortem samples.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Post-mortem brain analysis in humans revealed a lower expression of FGF1 and FGF2 in the dorsolateral PFC and the ACC of patients with MDD (Evans et al. 2004).”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Evans et al. 2004
Citations
Cites
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene
Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., et al. (2003) · Science · doi:10.1126/science.1083968 · Cited by 8,120
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma
Gilbertson, M. W., Shenton, M. E., Ciszewski, A., Kasai, K., Lasko, N. B., Orr, S. P., & Pitman, R. K. (2002) · Nature Neuroscience · doi:10.1038/nn958 · Cited by 1,635
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151
Lee, J., Duan, W., & Mattson, M. P. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01085.x · Cited by 975
Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia
Weickert, C. S., Hyde, T. M., Lipska, B. K., Herman, M. M., Weinberger, D. R., & Kleinman, J. E. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001308 · Cited by 532
Tomita, H., Vawter, M. P., Walsh, D. M., Evans, S. J., Choudary, P. V., Li, J., Overman, K. M., Atz, M. E., Myers, R. M., Jones, E. G., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.10.013 · Cited by 331
Self-citationThe neuropathology of primary mood disorder
Harrison, P. J. (2002) · Brain · doi:10.1093/brain/awf149 · Cited by 322
López-Figueroa, A. L., Norton, C. S., López-Figueroa, M. O., Armellini-Dodel, D., Burke, S., Akil, H., López, J. F., & Watson, S. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.017 · Cited by 296
Self-citation
Research works printed but not linked: 4
- Watson S. J. Patel P. Burke S. Herman J. Shaffer M. & Kwak S. (1988) in Short Course 1 Syllabus ed. Sunderman A. (Soc. Neurosci. Washington DC) pp. 4-29.
- Neal, C. R., Jr., Akil, H. & Watson, S. J., Jr. (2001) J. Chem. Neuroanat. 22, 219-249.11719021
- Parikh, V., Evans, D. R., Khan, M. M. & Mahadik, S. P. (2003) Schizophr. Res. 60, 117-123.12591576
- Dono, R. (2003) Am. J. Physiol. 284, R867-R881.
Cited by
Items 101–200 of 466
Inflammatory markers in women with postpartum depressive symptoms
Bränn, E., Fransson, E., White, R. A., Papadopoulos, F. C., Edvinsson, Å., Kamali‐Moghaddam, M., Cunningham, J. L., Poromaa, I. S., & Skalkidou, A. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24312 · Cited by 81
“…of the central nervous system (Ford‐Perriss, Abud, & Murphy, 2001) and dysregulation of several fibroblast growth fac‐ tor system transcripts (including FGF‐23) has been reported in frontal cortical regions of brains from human subjects with major depressive disorder (Evans et al., 2004).”
BackgroundMamdani, F., Rollins, B., Morgan, L., Myers, R. M., Barchas, J. D., Schatzberg, A. F., Watson, S. J., Akil, H., Potkin, S. G., Bunney, W. E., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2015.164 · Cited by 76
Self-citationAnisman, H., Merali, Z., & Stead, J. D. H. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.001 · Cited by 81
Self-citationKumar, R., Tang, Q., Müller, S. A., Gao, P., Mahlstedt, D., Zampagni, S., Tan, Y., Klingl, A., Bötzel, K., Lichtenthaler, S. F., et al. (2020) · Advanced Science · doi:10.1002/advs.201902372 · Cited by 71
Coordinated Messenger RNA/MicroRNA Changes in Fibroblasts of Patients with Major Depression
Garbett, K. A., Vereczkei, A., Kálmán, S., Brown, J. A., Taylor, W. D., Faludi, G., Korade, Ž., Shelton, R. C., & Mirnics, K. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.015 · Cited by 69
Weaver, I. C. G., Korgan, A. C., Lee, K., Wheeler, R. V., Hundert, A. S., & Goguen, D. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00041 · Cited by 63
“…many of growth factors, including BDNF (Duman and Monteggia, 2006; Castrén et al., 2007), CNTF (Kokoeva et al., 2005; Grunblatt et al., 2006), FGF (Evans et al., 2004), VGF (Thakker-Varia and Alder, 2009), VEGF (De Rossi et al., 2016), TGF (Lee and Kim, 2006), Wnt (Hiester et al., 2013), and IGF…”
BackgroundSalmaso, N., Stevens, H. E., McNeill, J., ElSayed, M., Ren, Q., Maragnoli, M. E., Schwartz, M. L., Tomasi, S., Sapolsky, R. M., Duman, R., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.02.026 · Cited by 67
“Increased hippocampal FGF2 levels are correlated with reduced manifestations of anxiety (11) and with positive response to treatment with the antidepressant fluoxetine (12,16).”
BackgroundDevelopmental effects of SSRIs: lessons learned from animal studies
Borue, X., Chen, J., & Condron, B. G. (2007) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2007.06.003 · Cited by 62
“Subsequent gene expression studies showed it to be significantly decreased in patients with major depression (Evans et al., 2004).”
BackgroundKhundakar, A., Morris, C., Oakley, A., McMeekin, W., & Thomas, A. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.052688 · Cited by 71
2D-DIGE proteome analysis on the platelet proteins of patients with major depression
Huang, T., Sung, M.-L., & Chen, T. (2014) · Proteome Science · doi:10.1186/1477-5956-12-1 · Cited by 71
“Recent studies demonstrate that BDNF [32,33], neurotrophin-3 (NT-3) [34], glial cell line-derived neurotrophic factor (GDNF) [35], fibroblast growth factor-2 (FGF-2) [36] and nerve growth factor (NGF) [37] influence adult hippocampal neurogenesis and regulate synaptic plasticity in neuronal networks involved in major…”
Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
Wu, A.-L., Feng, B., Chen, M. Z., Kolumam, G., Zavala-Solorio, J., Wyatt, S. K., Gandham, V. D., Carano, R. A. D., & Sonoda, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057322 · Cited by 67
“Modulation of FGFR pathway has been implicated in major mood depressive and other psychiatric disorders [36,37].”
BackgroundFibroblast Growth Factors in Depression
Deng, Z. H., Deng, S., Zhang, M.-R., & Tang, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00060 · Cited by 71
“Evans et al. found that the levels of FGF2 in the DLPFC and the AnCg of postmortem depressed patients were significantly lower than those of healthy controls (Evans et al., 2004).”
BackgroundResultInfluentialSealock, J., Lee, Y. A., Moscati, A., Venkatesh, S., Voloudakis, G., Straub, P., Singh, K., Feng, Y. A., Ge, T., Roussos, P., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.2959 · Cited by 71
Intracellular signaling pathways pave roads to recovery for mood disorders
Tanis, K. Q., & Duman, R. S. (2007) · Annals of Medicine · doi:10.1080/07853890701483270 · Cited by 69
Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues
Lin, X., Liu, Y. B., & Hu, H. (2017) · Biomedical Reports · doi:10.3892/br.2017.890 · Cited by 62
“Specifically, FGFs are involved in metabolic regulation and cell differentiation, proliferation and metabolism (1-6).”
BackgroundGallo, M., Defaus, S., & Andreu, D. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.010 · Cited by 64
The fibroblast growth factor system is downregulated following social defeat
Turner, C. A., Calvo, N., Frost, D. O., Akil, H., & Watson, S. J. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2007.10.041 · Cited by 68
“This finding is consistent with decreased levels of both ligands and receptors in the FGF system in post-mortem brains of individuals of major depressive disorder [7].”
BackgroundResultSelf-citationSalaria, S., Chana, G., Caldara, F., Feltrin, E., Altieri, M., Faggioni, F., Domenici, E., Merlo-Pich, E., & Everall, I. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.05.003 · Cited by 58
Marathe, S. V., D’almeida, P., Virmani, G., Bathini, P., & Alberi, L. A. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518789149 · Cited by 66
FGF2 blocks PTSD symptoms via an astrocyte-based mechanism
Xia, L., Zhai, M., Wang, L., Miao, D., Xia Shuang, Z. H. U., & Wang, W. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.08.048 · Cited by 65
Anterior cingulate pyramidal neurons display altered dendritic branching in depressed suicides
Hercher, C., Canetti, L., Turecki, G., & Mechawar, N. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.08.011 · Cited by 65
Fumagalli, F., Bedogni, F., Slotkin, T. A., Racagni, G., & Riva, M. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.005 · Cited by 54
Carter, B. S., Hamilton, D. E., & Thompson, R. C. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00139 · Cited by 56
“Alterations of astrocyte-enriched fibroblast growth factor (FGF) receptors observed here (upregulation of Fgfr3, downregulation of Fgfr1) may also be relevant to depression biology given the findings of altered expression of FGF receptors and ligands in depression (Evans et al., 2004).”
BackgroundSelf-citationBland, S. T., Schmid, M. J., Greenwood, B. N., Watkins, L. R., & Maier, S. F. (2006) · Neuroreport · doi:10.1097/00001756-200604240-00008 · Cited by 63
“Moreover, dysregulation of the FGF-2 system is associated with stressrelated disorders such as major depressive disorder (MDD) [15].”
BackgroundTranscriptional Changes Common to Human Cocaine, Cannabis and Phencyclidine Abuse
Lehrmann, E., Colantuoni, C., Deep-Soboslay, A., Becker, K. G., Lowe, R., Huestis, M. A., Hyde, T. M., Kleinman, J. E., & Freed, W. J. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000114 · Cited by 58
Tang, M., Lin, W., Zhang, J., Zhao, Y., & Li, Y. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.05.013 · Cited by 63
Ding, Y., Chang, L.-C., Wang, X., Guilloux, J.-P., Parrish, J., Oh, H., French, B. J., Lewis, D. A., Tseng, G. C., & Sibille, E. (2015) · Complex Psychiatry · doi:10.1159/000369974 · Cited by 61
Forkhead box O transcription factors as possible mediators in the development of major depression
Wang, H., Quirion, R., Little, P. J., Cheng, Y., Feng, Z., Sun, H., Xu, J., & Zheng, W. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.020 · Cited by 61
“…upstream molecules of FoxOs, including growth factors (such as BDNF, fibroblast growth factor and IGF-1), receptor tyrosine kinases, Akt and ERK1/2 produce beneficial effects against depression (Shi et al., 2012; Evans et al., 2004; Krogh et al., 2014; Mikoteit et al., 2014; Musazzi et al., 2010).”
Fibroblast growth factor 9 is a novel modulator of negative affect
Aurbach, E. L., Inui, E. G., Turner, C. A., Hagenauer, M. H., Prater, K. E., Li, J. Z., Absher, D., Shah, N., Blandino, P., Bunney, W. E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510456112 · Cited by 57
“This hypothesis is supported by gene expression profiling experiments in postmortem human brains that implicate the fibroblast growth factor (FGF) family and other neurotrophins in MDD (3, 4).”
BackgroundMethodSelf-citationGoswami, D. B., Jernigan, C. S., Chandran, A., Iyo, A. H., May, W. L., Austin, M. C., Stockmeier, C. A., & Karolewicz, B. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.010 · Cited by 59
“Previously, dysregulation of members of the FGF family have been observed in MDD (Evans et al., 2004; Gaughran et al., 2006; Tochigi et al., 2008).”
Engel, D. F., Zomkowski, A. D. E., Lieberknecht, V., Rodrigues, A. L. S., & Gabilan, N. H. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.02.013 · Cited by 60
“In the adult brain, FGF promotes neuronal survival and axonal branching, and it has been demonstrated that its expression is decreased in the hippocampus and frontal cortex of depressed patients (Evans et al., 2004).”
BackgroundKerman, I. A., Bernard, R., Bunney, W. E., Jones, E. G., Schatzberg, A. F., Myers, R. M., Barchas, J. D., Akil, H., Watson, S. J., & Thompson, R. C. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00135 · Cited by 59
“Tissue processing, and procedures for microarray experiments have been previously described (Evans et al., 2004; Tomita et al., 2004; Choudary et al., 2005; Bernard et al., 2011).”
MethodSelf-citationEffect of treatment on serum glial cell line-derived neurotrophic factor in bipolar patients
Zhang, X., Zhang, Z., Sha, W., Xie, C., Xi, G., Zhou, H., & Zhang, Y. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.03.003 · Cited by 58
“, systems are altered in various tissues including post-mortem brain, cerebrospinal fluid, and blood from patients with mood disorders (Hock et al., 2000; Evans et al., 2004; KauerSant'Anna et al., 2009).”
BackgroundEren-Koçak, E., Turner, C. A., Watson, S. J., & Akil, H. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.11.020 · Cited by 53
“individuals with major depressive disorder (MDD), FGF2 gene expression was downregulated in several cortical and limbic structures, including the hippocampus (5,6).”
Self-citationHisaoka, K., Tsuchioka, M., Yano, R., Maeda, N., Kajitani, N., Morioka, N., Nakata, Y., & Takebayashi, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.224683 · Cited by 57
The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs
Quesseveur, G., Gardier, A., & Guiard, B. (2013) · Current Drug Targets · doi:10.2174/13894501113149990209 · Cited by 51
“Moreover, treatment with antidepressants reduces this decreased expression of FGF-2 in MDD patients [211].”
BackgroundEmerging role of the FGF system in psychiatric disorders
Riva, M. A., Molteni, R., Bedogni, F., Racagni, G., & Fumagalli, F. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.001 · Cited by 56
Neuroplastin‐55 binds to and signals through the fibroblast growth factor receptor
Owczarek, S., Kiryushko, D. V., Larsen, M. H., Kastrup, J. S., Gajhede, M., Sandi, C., Berezin, V., Bock, E., & Soroka, V. (2009) · The FASEB Journal · doi:10.1096/fj.09-140509 · Cited by 55
“2 and 3), and that the FGFR system is involved in synaptic plasticity underlying mood disorders, including depression (51), we sought to determine whether Np55 might also be involved in the regulation of antidepressant-like activity in vivo.”
BackgroundMajor depression: emerging therapeutics
Sen, S., & Sanacora, G. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20043 · Cited by 47
Kōyama, Y. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00261 · Cited by 54
“Levels of BDNF (Dwivedi et al., 2003), GDNF (Otsuki et al., 2008; Zhang et al., 2008), and basic fibroblast growth factor (bFGF; Evans et al., 2004) are decreased in patients with depression, and relates to the reduced hippocampal neurogenesis.”
BackgroundLearning and Memory Depend on Fibroblast Growth Factor Receptor 2 Functioning in Hippocampus
Stevens, H. E., Jiang, G. Y., Schwartz, M. L., & Vaccarino, F. M. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.013 · Cited by 46
“We have shown that FGFR2 signaling in both the embryonic and adult hippocampus plays crucial roles for different aspects of learning and memory (19, 20, 34, 35, 70, 71).”
BackgroundWang, L., Li, X., Chen, X., Qin, X., Kardami, E., & Cheng, Y. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00377 · Cited by 53
Kalinina, J., Byron, S. A., Makarenkova, H. P., Olsen, S. K., Eliseenkova, A. V., Larochelle, W. J., Dhanabal, M., Blais, S., Ornitz, D. M., Day, L. A., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01780-08 · Cited by 50
“Recent data also implicate dysregulated FGF signaling in the etiology of neurodegenerative disorders, such as major depressive disorder and Parkinson’s disease (10, 63, 64).”
BackgroundChen, X., Feng, L., Cai, B., Chen, X., & Chen, G. (2017) · The Journal of Comparative Neurology · doi:10.1002/cne.24311 · Cited by 53
Biomarkers of Major Depressive Disorder: Knowing is Half the Battle
Malik, S., Singh, R., Arora, G., Dangol, A., & Goyal, S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.1.12 · Cited by 42
“relative to the controls on safe medicine [71-74].”
BackgroundElucidating the Possible Role of FoxO in Depression
Rana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03364-4 · Cited by 52
Sild, M., Ruthazer, E. S., & Booij, L. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.014 · Cited by 50
“, 2011) and misregulation of other trophic factors like fibroblast growth factor (FGF) (Evans et al., 2004; Turner et al., 2012) have been detected in MDD patients’ post-mortem brains as well as serum and plasma (Boku et al.”
BackgroundYao, Z., Zhang, Z., Zhang, J., Cai, X., Zheng, Z., Huang, Y., & Qu, S. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.01.005 · Cited by 51
“It was found that FGF2 mRNA levels in the hippocampus were significantly decreased in autopsy analysis of patients with major depression (MDD) (Gaughran et al., 2006; Evans et al., 2004; Turner et al., 2008).”
Smith, G. S., Gunning‐Dixon, F. M., Lotrich, F. E., Taylor, W. D., & Evans, J. D. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301333 · Cited by 48
“Fibroblast growth factor gene expression was shown to be dysregulated in post-mortem brain tissue from depressed patients (Evans et al, 2004).”
BackgroundGene expression patterns in brain cortex of three different animal models of depression
Urigüen, L., Arteta, D., Díez-Alarcia, R., Ferrer‐Alcón, M., Díaz, Á., Pazos, Á., & Meana, J. J. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2008.00402.x · Cited by 48
“Abnormal cortical gene expression in post-mortem tissues of depressed subjects evidences the implication of cortical gene changes in major depression (Evans et al. 2004; Laifenfeld et al. 2005).”
BackgroundAntidepressant-Like Effects of Erythropoietin: A Focus on Behavioural and Hippocampal Processes
Osborn, M., Rustom, N., Clarke, M., Litteljohn, D., Rudyk, C., Anisman, H., & Hayley, S. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072813 · Cited by 48
“In addition to BDNF, other trophic factors, including glial derived neurotrophic factor (GDNF) and fibroblast growth factor (FGF-2), might also play a role in depressive disorders [13,14].”
Ji, X., Wu, C., Wang, X., Liu, J., Jian-zhong, B., & Wang, D. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1674 · Cited by 47
“A previous study (45) demonstrated that the dysfunction of the FGF system in patients with major depression is not induced by antidepressants.”
Chaudhury, S., Aurbach, E. L., Sharma, V., Blandino, P., Turner, C. A., Watson, S. J., & Akil, H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411618111 · Cited by 46
“Moreover, FGF2 has been proposed as an endogenous anxiolytic and antidepressant that is depleted in the brain of depressed humans (24, 25).”
BackgroundSelf-citationLiberto, V. D., Frinchi, M., Verdi, V., Vitale, A., Plescia, F., Cannizzaro, C., Massenti, M. F., Belluardo, N., & Mudò, G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4498-0 · Cited by 44
Taetzsch, T., Brayman, V. L., & Valdez, G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.06.009 · Cited by 44
Shen, H., Zhang, T., Hong, B., Peng, D., Su, H. L., Lin, Z., Fang, Y., Jiang, K., Liu, X., & Li, H. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.07.035 · Cited by 44
“nd the hippocampus have been demonstrated in animal models f depression and postmortem studies in MDD [7,9,19].”
BackgroundMethodResultInfluentialBiomarkers for Psychiatric Disorders
Turck, C. W. (2009) · Springer eBooks · doi:10.1007/978-0-387-79251-4 · Cited by 44
Ciobanu, L. G., Sachdev, P. S., Trollor, J. N., Reppermund, S., Thalamuthu, A., Mather, K. A., Cohen‐Woods, S., & Baune, B. T. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.08.018 · Cited by 44
Llorens-Martín, M., Jurado-Arjona, J., Bolós, M., Pallas-Bazarra, N., & Ávila, J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.12.019 · Cited by 43
Kao, C., Hsu, Y., Liu, J., Lee, D., Chung, Y., & Chiu, I. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12292 · Cited by 37
“The dysregulation of FGF1 has been linked to major depressive disorders (Evans et al. 2004).”
BackgroundFibroblast growth factor 2 is necessary for the antidepressant effects of fluoxetine
Simard, S., Shail, P., MacGregor, J., Sayed, M. E., Duman, R. S., Vaccarino, F. M., & Salmaso, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204980 · Cited by 43
“Furthermore, no changes in FGF2 were noted in the post-mortem brains of individuals with mood disorders that were successfully treated with anti-depressant medication prior to death [14, 15, 18, 19].”
BackgroundBlackwood, C. A., Leary, M., Salisbury, A. J., McCoy, M. T., & Cadet, J. L. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.07.030 · Cited by 43
“Thus, it is intriguing to suggest that MDD and incubation of craving may represent behavioral manifestations of opposite FGF-mediated neurobiological phenomena.”
BackgroundInfluentialMemory of fearful events: the role of fibroblast growth factor-2 in fear acquisition and extinction
Graham, B. M., & Richardson, R. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.05.041 · Cited by 43
Woo, H. I., Lim, S.-W., Myung, W., Kim, D. K., & Lee, S.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0123-0 · Cited by 42
Tatro, E. T., Scott, E. R., Nguyen, T. B., Salaria, S., Banerjee, S., Moore, D. J., Masliah, E., Achim, C. L., & Everall, I. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010337 · Cited by 39
“, [39] reported dysregulation of the trophic factors fibroblast growth factor (FGF) 2 and 9 in the brains of individuals with MDD.”
BackgroundMcQuaid, R. J., McInnis, O. A., Matheson, K., & Anisman, H. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00358 · Cited by 40
“For example, biological correlates of suicide have included altered serotonin and GABA receptor variations (Anisman et al., 2012) as well as that of the neurotrophin FGF-2 (Evans et al., 2004).”
BackgroundResultMeta-analysis of genome-wide SNP- and pathway-based associations for facets of neuroticism
Kim, S. E., Kim, H., Yun, Y.-J., Heo, S. G., Cho, J., Kwon, M., Chang, Y., Ryu, S., Shin, H. C., Shin, C., et al. (2017) · Journal of Human Genetics · doi:10.1038/jhg.2017.61 · Cited by 41
The best-laid plans go oft awry: synaptogenic growth factor signaling in neuropsychiatric disease
Williams, A. J., & Umemori, H. (2014) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2014.00004 · Cited by 38
“…cord, ectopic neurons in hippocampal commissure (Dono et al., 1998; Ortega et al., 1998) None identified Decreased in anterior cingulate in MDD (Evans et al., 2004) FGF3 Inner ear development (Frenz et al., 2010), works cooperatively with FGF8 in zebrafish retinal development…”
BackgroundInfluentialShan, X., Chen, J., Dai, S., Wang, J., Huang, Z., Lv, Z., Wang, Q., & Wu, Q. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153269 · Cited by 40
Roles of exogenous and endogenous FGF-2 in animal models of depression
Jarosik, J., Legutko, B., Werner, S., Unsicker, K., & Halbach, O. V. B. U. (2011) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-2011-0588 · Cited by 40
“Along this line, it has been reported that the FGF system, including FGF-2, was the molecular ensemble most significantly altered in depressed individuals, across several cortical and subcortical regions (Evans et al., 2004).”
InfluentialRao, J. S., Chiappelli, J., Kochunov, P., Regenold, W. T., Rapoport, S. I., & Hong, L. E. (2014) · Neurodegenerative Diseases · doi:10.1159/000369214 · Cited by 40
Neonatal fibroblast growth factor treatment enhances cocaine sensitization
Clinton, S. M., Turner, C. A., Flagel, S. B., Simpson, D. N., Watson, S. J., & Akil, H. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.07.006 · Cited by 35
“We previously focused on the FGF family due to its profound perturbation in major depression (Evans et al., 2004).”
BackgroundSelf-citationMorrison, F. G., Miller, M. W., Wolf, E. J., Logue, M. W., Maniates, H., Kwasnik, D., Cherry, J. D., Svirsky, S. E., Restaino, A. C., Hildebrandt, A. M., et al. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.10.027 · Cited by 39
“Previous gene expression studies in postmortem brain tissue have identified a number of differentially regulated targets in depressed versus control samples [29-36], including increased levels of pro- and anti-inflammatory cytokine gene expression in the prefrontal cortex (BA 10) of MDD cases [37].”
BackgroundSoleimani, L., Roder, J., Dennis, J. W., & Lipina, T. V. (2007) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00358.x · Cited by 38
“Examples include several members of the fibroblast growth factor (FGF) family of cytokines as well as glycoprotein receptor pro- inflammatory cytokines (Dunn et al. 2005; Evans et al. 2004).”
BackgroundAn Astroglial Basis of Major Depressive Disorder: Molecular, Cellular, and Circuit Features
Lu, C., Ren, J., & Cao, X. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.07.017 · Cited by 37
Kamyshna, I. I., Pavlovych, L., & Kamyshnyi, O. (2021) · Endocrine Regulations · doi:10.2478/enr-2021-0002 · Cited by 37
Parthasarathy, G., Pattison, M. B., & Midkiff, C. C. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02681-x · Cited by 37
“Its expression has also been shown to be elevated in anterior cingulate cortex of patients with major depressive disorder (MDD) [55].”
InfluentialPsychiatric Disorders - Trends and Developments
(2011) · InTech eBooks · doi:10.5772/2330 · Cited by 35
Zhang, R., Ma, Z., Liu, K., Li, Y., Liu, D., Xu, L., Deng, X., Qu, R., Ma, Z., & Ma, S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.02.033 · Cited by 36
Musanabaganwa, C., Wani, A. H., Donglasan, J., Fatumo, S., Jansen, S., Mutabaruka, J., Rutembesa, E., Uwineza, A., Hermans, E. J., Roozendaal, B., et al. (2022) · Epigenomics · doi:10.2217/epi-2021-0310 · Cited by 35
Haljas, K., Amare, A. T., Alizadeh, B. Z., Hsu, Y., Mosley, T. H., Newman, A. B., Murabito, J. M., Tiemeier, H. W., Tanaka, T., van Duijn, C. M., et al. (2017) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000555 · Cited by 35
“aberrant glia cell function (47), and MDD patients have shown down-regulated FGFR2 in several brain regions (48).”
BackgroundWu, C.-K., Tseng, P.-T., Chen, Y.-W., Tu, K.-Y., & Lin, P.-Y. (2016) · Medicine · doi:10.1097/md.0000000000004563 · Cited by 33
The Role of Neurotrophic Factors in Pathophysiology of Major Depressive Disorder
Amidfar, M., Réus, G. Z., de Moura, A. B., Quevedo, J., & Kim, Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_14 · Cited by 34
Mansuy‐Aubert, V., Tolle, F., Delage-Mourroux, R., Fraîchard, A., Risold, P., & Jouvenot, M. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.004 · Cited by 34
Tsoory, M., Guterman, A., & Richter‐Levin, G. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22203 · Cited by 34
“dysregulation of several members of the fibroblast growth factor (FGF) family and their receptors was found among depressed patients, and antidepressants were reported to regulate FGF expression (Evans et al., 2004; Riva et al., 2005).”
BackgroundReduced GABA neuron density in auditory cerebral cortex of subjects with major depressive disorder
Smiley, J. F., Hackett, T. A., Bleiwas, C., Petkova, E., Stankov, A., Mann, J. J., Rosoklija, G. B., & Dwork, A. J. (2015) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2015.10.008 · Cited by 34
“…GABA-associated markers, reduced markers for neurotrophic support and increased inflammatory markers (Aston et al., 2005; Choudary et al., 2005; Duric et al., 2010; Evans et al., 2004; Guilloux et al., 2012; Sequeira et al., 2007; Sequeira et al., 2012; Shelton et al., 2011; Tripp et al., 2012).”
BackgroundVitale, G., Filaferro, M., Bonaventura, M. V. M. D., Ruggieri, V., Cifani, C., Guerrini, R., Simonato, M., & Zucchini, S. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117691456 · Cited by 35
“, 2006); furthermore, the antidepressant treatment opposes these effects and upregulates FGF-2 in humans (Evans et al., 2004) and in rodent models (Bachis et al.”
Heterogeneity in major depressive disorder: The need for biomarker-based personalized treatments
Suseelan, S., & Pinna, G. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.09.001 · Cited by 33
Kato, M., Okugawa, G., Wakeno, M., Takekita, Y., Nonen, S., Tetsuo, S., Nishida, K., Azuma, J., Kinoshita, T., & Serretti, A. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.06.006 · Cited by 33
“Reduced FGF2 expression was described in the hippocampus and frontal cortex of human subjects with MDD (Evans et al., 2004; Gaughran et al., 2006) as well as social defeat rats (Turner et al.”
BackgroundJürgenson, M., Aonurm‐Helm, A., & Zharkovsky, A. (2012) · Brain Research · doi:10.1016/j.brainres.2012.01.056 · Cited by 32
“Several recent studies have proposed a link between the FGF system and depression (Evans et al., 2004; Gaughran et al., 2006).”
BackgroundSNPs on Chips: The Hidden Genetic Code in Expression Arrays
Śliwerska, E., Meng, F., Speed, T. P., Jones, E. G., Bunney, W. E., Akil, H., Watson, S. J., & Burmeister, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.023 · Cited by 32
Self-citationMesdom, P., Colle, R., Lebigot, É., Trabado, S., Deflesselle, É., Fève, B., Becquemont, L., Corruble, E., & Verstuyft, C. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191021141057 · Cited by 31
Caffino, L., Mottarlini, F., Zita, G., Gawliński, D., Gawlińska, K., Wydra, K., Przegaliński, E., & Fumagalli, F. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15523 · Cited by 31
“This observation is intriguing because FGF-2 is involved in depression (Evans et al., 2004; Riva et al., 2005) and its expression is regulated by antidepressants (Bachis et al., 2008; Maragnoli et al., 2004).”
BackgroundHebda‐Bauer, E. K., Dokas, L. A., Watson, S. J., & Akil, H. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2019.06.005 · Cited by 31
“Our laboratory has shown that in humans and Sprague-Dawley rats, FGF2 gene expression is decreased in conjunction with anxiety and depression (Evans et al., 2004; Perez et al., 2009; Turner et al., 2008a, 2008b).”
BackgroundSelf-citationA study of the functional significance of epidermal growth factor in major depressive disorder
Tian, W., Zhang, J., Zhang, K., Yang, H., Sun, Y., Shen, Y., & Xu, Q. (2012) · Psychiatric Genetics · doi:10.1097/ypg.0b013e3283539550 · Cited by 31
“Microarray studies of the postmortem brains revealed that some family members of the fibroblast growth factor (FGF) were altered in patients with MDD (Evans et al., 2004).”
BackgroundDeletion of fibroblast growth factor 22 (FGF22) causes a depression-like phenotype in adult mice
Williams, A. J., Yee, P. P., Smith, M. C., Murphy, G. G., & Umemori, H. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.03.047 · Cited by 31
“Altered expression of, or mutations in, FGFs and their receptors have been implicated in the pathogenesis of many neuropsychiatric diseases, including depression (4), altered social behavior (5), seizures (6) and intellectual disability (6).”
BackgroundTseng, P., Chen, Y., Tu, K.-Y., Wang, H., Chung, W., Wu, C.-K., Hsu, S., Kuo, H.-C., & Lin, P. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.05.009 · Cited by 30
Xiao, L., Yang, X., & Loh, Y. P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00243 · Cited by 30
Depression-Associated Gene Negr1-Fgfr2 Pathway Is Altered by Antidepressant Treatment
Carboni, L., Pischedda, F., Piccoli, G., Lauria, M., Musazzi, L., Popoli, M., Mathé, A. A., & Domenici, E. (2020) · Cells · doi:10.3390/cells9081818 · Cited by 30
“Intriguingly, decreased expression of Fgfr2 in the dorsolateral prefrontal cortex (DLPFC) and in the anterior cingulate cortex were found in post-mortem brains in MDD patients [26].”
BackgroundPase, C. S., Teixeira, A. M., Roversi, K., Dias, V. T., Calabrese, F., Molteni, R., Franchi, S., Panerai, A. E., Riva, M. A., & Bürger, M. E. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.05.013 · Cited by 30
“For example, it has been demonstrated that major depressive and bipolar disorders are associatedwith a significant reduction of FGF-transcripts (including FGF-2) at the fronto-cortical level, as well as FGF receptors, in brain areas compared with healthy subjects [82].”
Background
Metadata
- Authors
- Evans, S. J., Choudary, P. V., Neal, C. R., Li, J. Z., Vawter, M. P., Tomita, H., Lopez, J. F., Thompson, R. C., Meng, F., Stead, J. D., Walsh, D. M., Myers, R. M., Bunney, W. E., Watson, S. J., Jones, E. G., & Akil, H.
- Affiliations
- University of California, Irvine (US)
- Department of Psychiatry and Mental Health Research Institute, University of Michigan, Ann Arbor, MI 48109; Human Genome Center, Stanford University, Palo Alto, CA 94304; Center for Neuroscience, University of California, Davis, CA 95616; and Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92697
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-10-13
- Volume
- 101
- Issue
- 43
- Pages
- 15506-15511
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC523463
- OpenAlex
- W2150092716
- Cited by
- 424
- References
- 38
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 20 · 2023: 15 · 2022: 19 · 2021: 21 · 2020: 10 · 2019: 22 · 2018: 20 · 2017: 26 · 2016: 15 · 2015: 23 · 2014: 15 · 2013: 20 · 2012: 20
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Michigan
- National Institutes of Health
- University of California, Davis
- University of California, Irvine
- National Institute of Mental Health (P50MH060398, #L99MH60398)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, gene expression dysregulation, frontal cortex, bipolar disorder, serotonin reuptake inhibitors, antidepressant mechanism, growth factor receptors, postmortem brain
- MeSH terms
- Adult, Aged, Aged, 80 and over, Major Depressive Disorder, Female, Fibroblast Growth Factors, Humans, Male, Middle Aged, Polymerase Chain Reaction, Selective Serotonin Reuptake Inhibitors, In Situ Hybridization, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.